Fusion Antibodies (LON:FAB) Shares Down 3.4% – Here’s What Happened

Fusion Antibodies plc (LON:FAB)’s stock price was down 3.4% during mid-day trading on Wednesday . The stock traded as low as GBX 14 and last traded at GBX 14. Approximately 225,728 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 491,605 shares. The stock had previously closed at GBX 14.50.

Fusion Antibodies Stock Performance

The stock has a market capitalization of £16.25 million, a PE ratio of -8.67 and a beta of 1.22. The firm has a 50 day moving average price of GBX 13.15 and a 200-day moving average price of GBX 13.76. The company has a quick ratio of 2.36, a current ratio of 1.80 and a debt-to-equity ratio of 92.42.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.